Robert C Doebele
14PUBLICATIONS
76CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (14)
Sort by Publication Date:
|Dec 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.Qianqian Hu, Lily L Remsing Rix, Bina Desai
|Aug 11, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder
|Nov 03, 2024
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.David Gonzalez-Martinez, Lee Roth, Thomas R Mumford
|Sep 25, 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.Nan Chen, Logan C Tyler, Anh T Le
|Jul 05, 2022
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.Gaia Bianco, Mairene Coto-Llerena, John Gallon
|Apr 20, 2022
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.Gaia Bianco, Mairene Coto-Llerena, John Gallon
Pageof 3
Frequent Collaborators
2 joint publications
Tejas Patil
2 joint publications
Niko Beerenwinkel
2 joint publications
Sumana Srivatsa
2 joint publications
Claudia Lengerke
2 joint publications
Martina Konantz
2 joint publications
Anh T Le
2 joint publications
Marianna Kruithof-de Julio
2 joint publications
Caner Ercan
2 joint publications
Mattia Marinucci
2 joint publications
John Gallon
